Announcements

  • Study sheds more light on delamanid role in treating MDR-TB

    By: Ben Dawes Ben Dawes , 7 years ago
    A phase 3 trial of , a newer oral drug for treating multidrug-resistant tuberculosis (MDR-TB), found no statistically significant reduction in time to sputum culture conversion when compared to placebo, but that it was safe and well tolerated.